-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2023-508635-31-00
5
2019-12-03
Hepatocellular Carcinoma
-
2023-504303-86-00
5
2019-11-21
High-risk hepatocellular carcinoma (HCC)
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2022-502658-15-00
5
2019-09-22
Resectable Stage II-IIIB Non-small cell lung cancer
-
2023-508264-29-00
5
2019-06-11
Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
-
2023-506733-30-00
4
2019-05-16
Multiple Myeloma relapsed and/or refractory
-
2023-507902-15-00
4
2019-03-26
Non-Small Cell Lung Cancer
-
2024-511204-16-00
5
2019-01-23
Metastatic breast cancer
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2024-512049-17-00
6
2018-09-05
Newly diagnosed MM patients >= 65 years old or ineligible for autologo
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-509354-58-00
5
2017-07-14
Mantle Cell Lymphoma
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2023-510434-83-00
6
2016-10-17
Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-506524-82-00
5
2015-10-21
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
-
2023-509709-63-00
4
2024-07-30
Chronic Kidney Disease and Albuminuria
-
2022-500918-25-00
5
2024-05-20
Marginal Zone Lymphoma
-
2022-501781-22-00
5
2024-02-09
Generalised lipodystrophy